SBI Securities’s Spero Therapeutics SPRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$74 Buy
61
+48
+369% +$65 ﹤0.01% 3654
2026
Q2
$29 Buy
13
+4
+44% +$10 ﹤0.01% 3779
2026
Q1
$21 Hold
9
– – ﹤0.01% 3758
2025
Q4
$21 Sell
9
-1
-10% -$2 ﹤0.01% 3770
2025
Q3
$19 Sell
10
-52
-84% -$114 ﹤0.01% 3930
2025
Q2
$180 Buy
62
+2
+3% +$3 ﹤0.01% 3351
2025
Q1
$43 Sell
60
-153
-72% -$129 ﹤0.01% 3688
2024
Q4
$219 Buy
+213
New +$253 ﹤0.01% 3205

Other funds holding SPRO

SBI Securities's SPRO Position: Q3 2026 in Review

SBI Securities increased its Spero Therapeutics (SPRO) stake by 369% in Q3 2026, buying an estimated $65 and bringing the position to 61 shares worth $74. The position accounts for ﹤0.01% of the portfolio, ranked #3654.

SBI Securities first reported a position in SPRO in Q4 2024 and has held it in 8 quarters since. The position peaked at $219 in Q4 2024. 61 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

  • SBI Securities held 61 shares of Spero Therapeutics worth $74 as of Q3 2026.
  • SBI Securities bought 48 Spero Therapeutics shares in Q3 2026, an estimated $65.
  • Spero Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3654 holding.
  • SBI Securities first reported a position in Spero Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • SBI Securities's Spero Therapeutics position peaked at $219 in Q4 2024.
  • 61 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.